Li Jin-Long, Ge Long, Ma Ji-Chun, Zeng Qiao-Ling, Yao Lu, An Ni, Ding Jie-Xian, Gan Yu-Hong, Tian Jin-Hui
Evidence-Based Medicine Center of Lanzhou University, Lanzhou 730000, Gansu, China.
Syst Rev. 2014 Jun 7;3:58. doi: 10.1186/2046-4053-3-58.
The number of systematic reviews (SRs)/meta-analyses (MAs) has increased dramatically in China over the past decades. However, evaluation of quality of reporting of systematic reviews published has not been undertaken. The objective of this study is to evaluate the quality of reporting of SRs/MAs assessing efficacy and/or harms of clinical interventions published in "evidence-based" Chinese journals.
Web-based database searches were conducted for the Chinese Journal of Evidence-based Medicine, the Journal of Evidence-Based Medicine, the Chinese Journal of Evidence Based Pediatrics, and the Chinese Journal of Evidence-Based Cardiovascular Medicine. SRs/MAs assessing efficacy and/or harms of clinical interventions were included. The cut-off was December 31st 2011. The PRISMA statement was applied to assess the quality of reporting. Each item was assessed as follows: 'Yes' for total compliance, scored '1'; 'partial' for partial compliance, scored '0.5'; and 'No' for non-compliance, scored '0'. The review was considered to have major flaws if it received a total score of ≤15.0, minor flaws if it received a total score of 15.5 to 21.0, and minimal flaws if it received a total score 21.5 to 27.0. Odds ratios were used for binary variables, and the mean difference was used for continuous variables. Analyses were performed using RevMan 5.0 software.
Overall, 487 SRs/MAs were identified and assessed. The included reviews had medium quality with minor flaws based on PRISMA total scores (range: 8.5-26.0; mean: 19.6 ± 3.3). The stratified analysis showed that SRs/MAs with more than 3 authors, from a university, hospital + university cooperation, multiple affiliations (≥2), and funding have significantly higher quality of reporting of SRs/MAs; 58% of the included reviews were considered to have minor flaws (total score of 15.6 to 21.0). Only 9.6% of reviews were considered to have major flaws. Specific areas needing improvement in reporting include the abstract, protocol and registration, and characteristics of the search.
The reporting of SRs published in "evidence-based" Chinese journals is poor and needs to be improved in order for reviews to be useful. SR authors should use the PRISMA checklist to ensure complete and accurate accounts of their SRs.
在过去几十年里,中国的系统评价(SRs)/荟萃分析(MAs)数量急剧增加。然而,尚未对已发表的系统评价报告质量进行评估。本研究的目的是评估发表在“循证”中文期刊上的评估临床干预措施疗效和/或危害的SRs/MAs的报告质量。
通过基于网络的数据库检索《中国循证医学杂志》《循证医学杂志》《中国循证儿科杂志》和《中国循证心血管医学杂志》。纳入评估临床干预措施疗效和/或危害的SRs/MAs。截止日期为2011年12月31日。应用PRISMA声明评估报告质量。每个项目的评估如下:完全符合为“是”,得1分;部分符合为“部分”,得0.5分;不符合为“否”,得0分。如果综述的总分≤15.0,则认为存在重大缺陷;如果总分在15.5至21.0之间,则认为存在轻微缺陷;如果总分在21.5至27.0之间,则认为存在最小缺陷。二分类变量使用比值比,连续变量使用均值差。使用RevMan 5.0软件进行分析。
总体而言,共识别并评估了487篇SRs/MAs。根据PRISMA总分(范围:8.5 - 26.0;均值:19.6±3.3),纳入的综述质量中等,存在轻微缺陷。分层分析表明,作者人数超过3人、来自大学、医院+大学合作、多个单位(≥2个)以及有资金支持的SRs/MAs的报告质量显著更高;58%的纳入综述被认为存在轻微缺陷(总分15.6至21.0)。只有9.6%的综述被认为存在重大缺陷。报告中需要改进的具体领域包括摘要、方案和注册以及检索特征。
发表在“循证”中文期刊上的SRs报告质量较差,需要改进才能使综述发挥作用。SR作者应使用PRISMA清单以确保其SRs的完整准确描述。